These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 15996019)
1. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. Huang YH; Shang BY; Zhen YS World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675 [TBL] [Abstract][Full Text] [Related]
4. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule]. Liu XY; Zhen YS Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099 [TBL] [Abstract][Full Text] [Related]
5. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11]. Wang FQ; Shang BY; Zhen YS Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin. Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325 [TBL] [Abstract][Full Text] [Related]
7. [Inhibitory effect of lidamycin on growth of colon carcinoma 26 and hepatic metastasis in mice]. Liu XJ; Dai Y; Shang Y; Li Y; Zhen YS Ai Zheng; 2005 Jun; 24(6):641-5. PubMed ID: 15946470 [TBL] [Abstract][Full Text] [Related]
8. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma. Gao R; Li L; Shang B; Zhao C; Sheng W; Li D Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234 [TBL] [Abstract][Full Text] [Related]
9. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin. Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664 [TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM. Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754 [TBL] [Abstract][Full Text] [Related]
11. Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Wang Z; He Q; Liang Y; Wang D; Li YY; Li D Biochem Pharmacol; 2003 Jun; 65(11):1767-75. PubMed ID: 12781328 [TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase. Fengqiang W; Boyang S; Yongsu Z Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678 [TBL] [Abstract][Full Text] [Related]
13. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody]. Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952 [TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Chen J; Ouyang ZG; Zhang SH; Zhen YS Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403 [TBL] [Abstract][Full Text] [Related]
15. [Characterization of cell death induced by anticancer antibiotic lidamycin in human hepatoma BEL-7402 cells]. He QY; Liang YY; Wang DS; Li DD Yao Xue Xue Bao; 2001 Mar; 36(3):174-8. PubMed ID: 12580082 [TBL] [Abstract][Full Text] [Related]
16. The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy. Li L; Hu L; Zhao CY; Zhang SH; Wang R; Li Y; Shao RG; Zhen YS Bioconjug Chem; 2018 Sep; 29(9):3104-3112. PubMed ID: 30105903 [TBL] [Abstract][Full Text] [Related]
17. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs]. Shang BY; Shang Y; Zhen YS; Chen SZ Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022 [TBL] [Abstract][Full Text] [Related]
18. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity. Zheng YB; Shang BY; Li Y; Zhen YS Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754 [TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor. Sheng W; Shang Y; Miao Q; Li Y; Zhen Y Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154 [TBL] [Abstract][Full Text] [Related]
20. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30 Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]